Compare Abeona Therapeutics Inc (ABEO) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Snap On Incorporated — how do they compare? Abeona Therapeutics Inc trades at $7.36 (market cap $421.19M), while Snap On Incorporated trades at $407.8 (market cap $21.30B). The key difference: Snap On Incorporated is far larger — about 50.6× Abeona Therapeutics Inc's market cap, and Snap On Incorporated pays a 2.37% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SNA | |
|---|---|---|
Market Cap | $421.19M | $21.30B |
Sector | Health | Technology |
52-Week High | $7.45 | $419.31 |
52-Week Low | $4.17 | $321.38 |
Enterprise Value | $276.10M | $20.93B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Snap-on (SNA) trades at $407.04, down 0.99% today, with a bullish technical signal from moving averages and support near $406. The company reported strong Q2 2026 earnings of $4.96 per share, beating estimates, with organic sales growth of 3% and a net income margin of 19.6%. Recent acquisitions like Diesel Laptops for $100 million aim to expand its diagnostics reach.
The outlook remains positive with a consensus price target of $455.33, implying 12% upside, supported by robust cash flow and dividend payments. Key risks include integration costs from acquisitions and premium valuation multiples, while softer OEM demand and economic sensitivity could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
